RNA vs STTK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

RNA

52.1
AI Score
VS
RNA Wins

STTK

44.8
AI Score

Investment Advisor Scores

RNA

52score
Recommendation
HOLD

STTK

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RNA STTK Winner
Net Income -36.82M -29.92M STTK
Operating Income -39.90M -31.70M STTK
ROE -17.2% -14.2% STTK
ROA -13.1% -13.6% RNA
Total Assets 280.51M 220.67M RNA
Cash 72.33M 63.30M RNA
Current Ratio 8.73 27.59 STTK
Free Cash Flow -37.20M -23.75M STTK

Relative Price Performance (Last 90 Days)

RNA 1M: -44.0% · 3M: -39.4% STTK 1M: -4.1% · 3M: -8.4%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 24

RSI (14): 23.6 · Price: $7.88

STTK

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 51.3 · Price: $6.63

Fundamentals Snapshot

Metric RNA STTK
Market Cap — —
Forward P/E -1.0 -12.9
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% -0.7%
Gross Margin -0.6% -38.2%
Operating Margin -7.5% -55.7%
EPS -5.44 -0.44
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.